Cefoperazone-treated mice as an experimental platform to assess differential virulence ofClostridium difficilestrains
- 5 November 2011
- journal article
- Published by Taylor & Francis in Gut Microbes
- Vol. 2 (6) , 326-334
Abstract
The toxin-producing bacterium C. difficile is the leading cause of antibiotic-associated colitis, with an estimated 500,000 cases C. difficile infection (CDI) each year in the US with a cost approa...Keywords
This publication has 42 references indexed in Scilit:
- Fourteen-Genome Comparison Identifies DNA Markers for Severe-Disease-Associated Strains of Clostridium difficileJournal of Clinical Microbiology, 2011
- Tigecycline Exhibits Inhibitory Activity against Clostridium difficile in the Colon of Mice and Does Not Promote Growth or Toxin ProductionAntimicrobial Agents and Chemotherapy, 2011
- Serine-71 phosphorylation of Rac1/Cdc42 diminishes the pathogenic effect ofClostridium difficiletoxin ACellular Microbiology, 2009
- Distinctive Profiles of Infection and Pathology in Hamsters Infected with Clostridium difficile Strains 630 and B1Infection and Immunity, 2009
- Antibiotic Treatment of Clostridium difficile Carrier Mice Triggers a Supershedder State, Spore-Mediated Transmission, and Severe Disease in Immunocompromised HostsInfection and Immunity, 2009
- Reproducible Community Dynamics of the Gastrointestinal Microbiota following Antibiotic PerturbationInfection and Immunity, 2009
- Toxin B is essential for virulence of Clostridium difficileNature, 2009
- Comparative Efficacies of Rifaximin and Vancomycin for Treatment of Clostridium difficile -Associated Diarrhea and Prevention of Disease Recurrence in HamstersAntimicrobial Agents and Chemotherapy, 2008
- The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genomeNature Genetics, 2006
- Epidemics of Diarrhea Caused by a Clindamycin-Resistant Strain ofClostridium difficilein Four HospitalsNew England Journal of Medicine, 1999